SCHEMBL5801249

SCHEMBL5801249

CCOC(=O)c1nocc1CCl

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
HTT P42858 2/20 0.41
TARBP2 Q15633 4/20 0.40
HPGD P15428 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP1A2 P05177 2/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
XBP1 P17861 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TLR9 Q9NR96 1/20 0.38
TSHR P16473 1/20 0.37
PDE4A P27815 1/20 0.37
GLP1R P43220 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30080002 0.85 KDM4E (0.41) LMNAMAPTHTTTARBP2HPGD
SCHEMBL30487833 0.84 TARBP2 (0.40) LMNAMAPTSMN1; SMN2HTTTARBP2
SCHEMBL23986023 0.80 HDAC4 (0.42) LMNAMAPTHTTTARBP2HPGD
SCHEMBL6873803 0.80 HPGD (0.43) LMNAMAPTSMN1; SMN2HTTTARBP2
SCHEMBL8920076 0.78 CA12 (0.46) LMNASMN1; SMN2HTTTARBP2HPGD
SCHEMBL22727456 0.77 TARBP2 (0.44) MAPTHTTTARBP2HPGDKDM4E
SCHEMBL26921830 0.77 HTT (0.46) LMNAMAPTSMN1; SMN2HTTTARBP2
SCHEMBL30173675 0.76 HDAC4 (0.42) MAPTHTTTARBP2HPGDKDM4E
SCHEMBL16571753 0.75 HTT (0.48) LMNAMAPTHTTTARBP2HPGD
SCHEMBL23990453 0.75 CYP1A2 (0.42) MAPTHTTTARBP2HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211739-A1 Use of selective P2X7 receptor antagonists ABBOTT LABORATORIES 2006-09-21 US disclosed
WO-2006086229-A1 THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS ABBOTT LABORATORIES (US) 2006-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211739-A1 Use of selective P2X7 receptor antagonists P2RX1, P2RX3, P2RX7 LMNA 3709/4885MAPT 2826/4885SMN1; SMN2 856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.